



SASBT Abstract Writing Series

The Methods Section Karin van den Berg 20 January 2021



University of California San Francisco

Some slides are copied with permission from the ITAPS and Fogarty programs





Writer's Block:

When your imaginary friends refuse to talk to you Can be the easiest and most straightforward to write



 Can be written in you are stuck with other sections, when you have writer's block







- It is where you share the recipe for your study
- Describes how you did the study with enough detail for the reader to judge the study's strengths and weaknesses
- Others must:
 - Understand what you did
 - Replicate what you did more or less
 - Don't give to much detail





- Four main points you need to explain:
 - Study Design & Setting (what kind of study you did)
 - Participant and how you selected them (sampling)
 - What measurements you did
 - Lab tests
 - Questionnaires
 - Observations
 - Analysis



- Do not present results in Methods section
 - For biomedical abstracts and paper, the description of your participants / samples is usually included in the Results Section, not in Methods
- But, must linked to Results section
 - If you add something to the Results, then add it to Methods
 - If you decide not to add a specific outcome to Results, then delete it from Methods

So, Where To Start??

- Ideally, make notes of everything you did
 - What is the research question
 - What variables did you use
 - Where there ones you wanted to use but did not
 - Where there ones you included initially but then excluded?
- Then read (good) papers and abstracts on your topic

Copy With Pride!!

Study Design

- Ok, so back to the 4 sections of the Methods:
 - Study Design & Setting (what kind of study you did)
 - Participant and how you selected them (sampling)
 - What measurements you did
 - Analysis
- Pivotal / Most important sentence of Methods
- Can occasionally be the last sentence of your Introduction
 - If it is, don't repeat it here

Types of Study Design

- Basic study designs:
 - Cross-sectional survey- include surveillance unless sentinel surveillance over time (e.g., nationally representative 2-stage cluster surveillance study)
 - Case-control study
 - Cohort study: longitudinal vs. retrospecti
 - Randomized controlled trial
 - Before-after study
- Combinations (describe both)
- Special cases
 - Secondary data analysis

Study Setting

- Geography
 - What areas were included in your study
 - Branch / zone / whole of SANBS / whole of South Africa
 - What ar the unique characteristics of the area included in the study
- Facility or Agency
 - ✤ Was the study done at SANBS / Hospital / General Public, etc
- Time frame
 - What period of time does your study cover

Participants & Sampling

- Ok, on to the next section of the Methods:
 - Study Design & Setting (what kind of study you did)
 - Participant and how you selected them (sampling)
 - What measurements you did
 - Analysis
- Need to tell the reader/audience not only
 - Who you included, but also
 - Who you excluded,
 - Where you found them and
 - How you selected them
 - Time frame of sampling

Participants are chosen randomly either through a random number table or putting all names in a hat.

SAMPLING BIAS

Sampling

Measurements

- Ok, on to the next section of the Methods:
 - Study Design & Setting (what kind of study you did)
 - Participant and how you selected them (sampling)
 - What measurements you did
 - Analysis
- How did you obtain your data?
 - Laboratory tests
 - Observations
 - Record review data extracts
 - Questionnaires / Surveys

Measurements – Questionnaires & Surveys

- How was it developed
 - Standardized
 - Developed in one language, translated/back- translated
 - Pilot tested—for comprehension
- Where administered and by whom
 - Self- or interviewer administered
 - Administered in a private setting by trained interviewers in local languages of x,y,z
- How long did it take?
- Other details: entered directly, PDA, ACASI

I spend some time on this as doing questionnaires and surveys are **<u>EXTREMELY</u>** complex and should only be done with expert support

Measurements – Variables

• Remember the ideal research question:

In a population of X is Y (predictor variable) associated with Z (outcome variable)

- Already spoke about the participants
- Should mention your main **PREDICTOR** variable, e.g.:
 - Demographic characteristics
 - Risk factors
 - Specefic types of questions

Information was collected on the following: basic demographics, self reported risk behavior, health seeking behavior; being physically forced to have sex, being otherwise coerced to have sex, but not physically etc.

Measurements

- Laboratory methods
 - Usually separate subheading
 - Screening and confirmatory tests
 - Where performed and by whom
 - Manufacturer of tests
 - Product name (company name, city, state, or country)
 - HIV1/2 STAT-PAK Rapid test (Inverness Medical, Princeton, NJ)
 - Reference new, experimental tests
- Give specific information on your OUTCOME variable, e.g.:

Acute HIV Infection was defined as antibody negative, PCR positive test results followed by antibody seroconversion...

Data Analysis & Statistical Methods

• Ok, on to the next section of the Methods:

- Study Design & Setting (what kind of study you did)
- Participant and how you selected them (sampling)
- What measurements you did
- Analysis
- Data entered
 - Where,
 - What program,
 - Exported into what (e.g., SAS version x [Cary, North Carolina]) for analysis
- Statistical tests performed
 - Univariate distribution of factors i.e. Simple frequencies
 - Bivariate (one predictor and one outcome)
 - Stratified analysis
 - Multivariable analysis

Ethical Considerations

- Often at end section on participants, could also be last sentence of Methods
- **MUST** have if reporting on surveys / questionnaires
- Informed consent (if not covered in the section on study population)
- Special considerations:
 - Persons with HIV considered to be a vulnerable population
 - Persons younger than 18
 - Employees where investigator is the employer
 - Persons in prison

- Study Design & Setting
- Participant and how you selected them
- What measurements you did
- Analysis
- A retrospective review using frequency analysis of laboratory data was performed.
- Batch screening of random donor samples was performed to identify rare types, using extended phenotyping by manual tube indirect antiglobulin and enzyme techniques.
- Results were captured on Meditech, the SANBS operating platform, and extracted to the SANBS Business Intelligence System.
- Screening outcome was assessed by comparing the number of donors screened to the number of rare donors identified.
- Rare units issued by the SARDP from January 2016 to October 2018 are presented, along with an analysis of the number of the active donors.

- Study Design & Setting
- Participant and how you selected them
- What measurements you did
- Analysis
- We performed a retrospective, descriptive study of the primary activities performed by the VRL between October 2015 and January 2019, focusing on the MATHS case control study.
- Laboratory data was retrieved from the Study Management System and laboratory records.
- Employee perspectives on challenges and benefits were sourced from a semi-structured interview.

- Study Design & Setting
- Participant and how you selected them
- What measurements you did
- Analysis
- We extracted data on all RBC units issued for the period January to December 2018 from the SANBS Business Intelligence System.
- We analyzed predictors of group O product issues to non-group O patients, including hospital type, issue priority, patient gender, geographical zone and the days' stock on hand using summary statistics in Excel.
- Significance of associations were determined using the chi-square test.

- Study Design & Setting
- Participant and how you selected them
- What measurements you did
- Analysis
- Blood donations previously confirmed as HIV-positive were further classified as acute (Ab-/RNA+), recent (AB+/RNA+, LAg recent), longstanding (Ab+/RNA+, LAg longstanding) and potential Elite Controller (Ab+/RNA-) HIV cases through HIV antibody (PrISM, Abbott), HIV RNA individual donation nucleic acid testing(NAT) (Procleix, Grifols) and LAg avidity testing.
- Stored plasma of these donations were tested for four ART drugs using qualitative liquid chromatography-tandem mass spectrometry (sensitivity 0. 0.02 μg/mL).
- Chi-square tests were used to assess the association of gender, ethnicity, age, geographic area, donor type, donor clinic type and HIV case type with ARV non-disclosure.

- Study Design & Setting
- Participant and how you selected them
- What measurements you did
- Analysis
- Plasma samples from HIV seropositive FT donors during calendar years 2012 through 2016 were tested with a limiting antigen avidity (LAg) assay (Sedia Biosciences, Portland OR).
- We used a cutoff of 1.50 normalized optical density units corresponding to an incidence "window" of 129 days.
- Incidence was calculated as cases/1,000 PY of which numerator cases were recent infections as classified by the LAg assay.
- Each uninfected donor contributed the full 129-day person-time to the denominator while recently infected donors contributed half that.
- We used multiple imputation to adjust incidence for missing LAg results for 414 (7%) confirmed HIV-positive donors.
- Donors classified as longstanding HIV were excluded from both the numerator and denominator. 95% confidence intervals were calculated using the Poisson method.

ANY OTHER QUESTIONS??

THANK YOU!

